"Fingolimod Hydrochloride" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A sphingosine-derivative and IMMUNOSUPPRESSIVE AGENT that blocks the migration and homing of LYMPHOCYTES to the CENTRAL NERVOUS SYSTEM through its action on SPHINGOSINE 1-PHOSPHATE RECEPTORS. It is used in the treatment of MULTIPLE SCLEROSIS.
| Descriptor ID |
D000068876
|
| MeSH Number(s) |
D02.033.100.700.350 D02.033.455.706.431 D02.092.063.700.350
|
| Concept/Terms |
Fingolimod Hydrochloride- Fingolimod Hydrochloride
- Hydrochloride, Fingolimod
- 2-Amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol hydrochloride
|
Below are MeSH descriptors whose meaning is more general than "Fingolimod Hydrochloride".
Below are MeSH descriptors whose meaning is more specific than "Fingolimod Hydrochloride".
This graph shows the total number of publications written about "Fingolimod Hydrochloride" by people in this website by year, and whether "Fingolimod Hydrochloride" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2011 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 1 | 1 | 2 |
| 2017 | 9 | 2 | 11 |
| 2018 | 8 | 4 | 12 |
| 2019 | 7 | 1 | 8 |
| 2020 | 2 | 3 | 5 |
| 2021 | 1 | 2 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Fingolimod Hydrochloride" by people in Profiles.
-
Serological response to SARS-CoV-2 vaccination in multiple sclerosis patients treated with fingolimod or ocrelizumab: an initial real-life experience. J Neurol. 2022 Jan; 269(1):39-43.
-
The outcome of a national MS-Covid-19 study: What the Turkish MS cohort reveals? Mult Scler Relat Disord. 2021 Jul; 52:102968.
-
Impact of COVID-19 on multiple sclerosis care and management: Results from the European Committee for Treatment and Research in Multiple Sclerosis survey. Mult Scler. 2022 01; 28(1):132-138.
-
Managing multiple sclerosis in the Covid19 era: a review of the literature and consensus report from a panel of experts in Saudi Arabia. Mult Scler Relat Disord. 2021 Jun; 51:102925.
-
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies. CNS Drugs. 2021 03; 35(3):317-330.
-
COVID-19 in multiple sclerosis patients treated with dimethyl fumarate. J Neurol. 2021 Sep; 268(9):3132-3134.
-
Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. Ann Neurol. 2021 04; 89(4):780-789.
-
Safety of disease-modifying treatments in SARS-CoV-2 antibody-positive multiple sclerosis patients. Mult Scler Relat Disord. 2021 Apr; 49:102754.
-
[Pharmacovigilance update]. Rev Med Suisse. 2021 Jan 13; 17(720-1):80-84.
-
Rationale for the use of sphingosine analogues in COVID-19 patients. Clin Med (Lond). 2021 Jan; 21(1):e84-e87.